Skip to main content
SpringerLink
Log in

Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33(9):905–24.

    Article  PubMed  Google Scholar 

  2. Palozzo AC. New drugs—how much are they worth? the Italian registries: a model to evaluate appropriateness and effectiveness. Eur J Hosp Pharm. 2012;19:398–403.

    Article  Google Scholar 

  3. Rapporto Osmed 2014 (annual nationwide report). http://www.agenziafarmaco.gov.it/it/content/rapporti-osmed-luso-dei-farmaci-italia. Accessed 8 Jan 2016

  4. Messori A, De Rosa M, Pani L. Alternative pricing strategies for cancer drugs. JAMA. 2015;313(8):857.

    Article  PubMed  Google Scholar 

  5. Messori A, De Rosa M, Fadda V, Pani L. Effectiveness and cost effectiveness of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3838–9.

    Article  PubMed  Google Scholar 

  6. Trojniak MP, Jirillo A. Does chemotherapy have a role after erlotinib treatment in NSCLC? Lung Cancer. 2012;75(1):136.

    Article  PubMed  Google Scholar 

  7. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981–8.

    Article  CAS  PubMed  Google Scholar 

  8. Messori A, Fadda V, Maratea D, Trippoli S. The Italian way to evidence-based demonstration of equivalence as a prerequisite for conducting procurement tendering within the NHS. 1 July 2014. http://www.bmj.com/content/347/bmj.f4951/rr/759376. Accessed 8 Jan 2016

  9. Messori A, Trippoli S, Fadda V, Maratea D. Producing evidence in support of disinvestment: the experience of the Tuscany region in Italy. Eur J Intern Med. doi:10.1016/j.ejim.2015.10.021 (Epub 9 Nov 2015).

Download references

Author information

Authors and Affiliations

  1. Veneto Oncology Institute IRCCS, Padua, Italy

    Angelo Claudio Palozzo

  2. HTA Unit, Regional Health Service, Florence, Italy

    Andrea Messori

  3. SIFACT, Italian Society of Clinical Pharmacy and Therapeutics, via Farini 81, 20100, Milan, Italy

    Angelo Claudio Palozzo & Andrea Messori

Authors
  1. Angelo Claudio Palozzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Messori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Messori.

Ethics declarations

Conflicts of interest

Angelo Claudio Palozzo and Andrea Messori declare that they have no conflict of interest that are directly relevant to the content of this letter.

Funding

No funding was received for the preparation of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palozzo, A.C., Messori, A. Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”. PharmacoEconomics 34, 419–420 (2016). https://doi.org/10.1007/s40273-015-0376-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-015-0376-6

Keywords

Search

Navigation